224 related articles for article (PubMed ID: 20203451)
1. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Zamorano J; Erdine S; Lopez AP; Kim JH; Al Khadra A; Westergaard M; Sutradhar S; Yunis C;
Postgrad Med; 2010 Mar; 122(2):7-15. PubMed ID: 20203451
[TBL] [Abstract][Full Text] [Related]
2. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
[TBL] [Abstract][Full Text] [Related]
3. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
4. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Richard Hobbs FD; Gensini G; John Mancini GB; Manolis AJ; Bauer B; Genest J; Feldman RD; Harvey P; Jenssen TG; da Silva PM;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):472-80. PubMed ID: 19407658
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin + amlodipine: new drug. Just a commercial ploy.
Prescrire Int; 2007 Jun; 16(89):105. PubMed ID: 17582926
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
7. Changes in calculated coronary heart disease risk using proactive multifactorial intervention versus continued usual care in Latin-American and non-Latin-American patients enrolled in the CRUCIAL trial.
Pavia A; Zamorano J; Sutradhar S; Yunis C;
Curr Med Res Opin; 2012 Oct; 28(10):1667-76. PubMed ID: 22991979
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
9. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Hradec J; Zamorano J; Sutradhar S
Curr Med Res Opin; 2013 Jun; 29(6):589-96. PubMed ID: 23464930
[TBL] [Abstract][Full Text] [Related]
10. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Zamorano J; Erdine S; Pavia A; Kim JH; Al-Khadra A; Westergaard M; Sutradhar S; Yunis C;
Curr Med Res Opin; 2011 Apr; 27(4):821-33. PubMed ID: 21306285
[TBL] [Abstract][Full Text] [Related]
11. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
[TBL] [Abstract][Full Text] [Related]
12. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Frishman WH; Zuckerman AL
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):675-81. PubMed ID: 15350169
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Cowie MR
Int J Clin Pract; 2005 Jul; 59(7):839-46. PubMed ID: 15963213
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
[TBL] [Abstract][Full Text] [Related]
16. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
17. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
18. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous treatment of blood pressure and cholesterol beats the 'SILO' approach in lowering cardiovascular risk: results of the CRUCIAL study.
Aalbers J
Cardiovasc J Afr; 2011; 22(2):101. PubMed ID: 21556456
[No Abstract] [Full Text] [Related]
20. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
